abstract design accord is a parallel group, randomized trial designed to investigate whether intensive glycemic therapy with a target hba1c of <6.0% versus standard therapy with a target of 7.0 to 7.9% reduces cardiovascular disease (cvd) morbidity, mortality, and microvascular complications in participants with type 2 diabetes.